US Pharma MarketingPost-Hoc: What brought down the FDA commissioner
Marty Makary resigned as FDA commissioner Tuesday. The next commissioner will inherit the same punishing contradictions, and a weaker, politicized agency. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
Marty Makary never stood a chance.
Over the last few days, the now-former FDA commissioner had been left to twist in the wind, after headlines emerged late last week that President Donald Trump had signed ...
Source: Endpoints News